Mirum Pharmaceuticals, Inc. (MIRM) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, commercializing three approved medicines: LIVMARLI (maralixibat), Cholbam (cholic acid), and Ctexli (chenodiol, formerly Chenodal). The company also has a development pipeline including volixibat and MRM-3379. As of September 30, 2025, the company had 51,393,574 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $133,010 | $90,377 | $372,380 | $237,474 |
| Net Income (Loss) | $2,905 | $(14,235) | $(17,633) | $(64,152) |
| Operating Income (Loss) | $2,603 | $(12,684) | $(17,569) | $(63,384) |
| EPS (Diluted) | $0.05 | $(0.30) | $(0.35) | $(1.36) |
| Cash & Equivalents | $282,021 | $222,503 | N/A | |
| Total Investments | $95,997 | $70,338 | ||
| Convertible Notes (Principal) | $316,233 | $316,250 | N/A | |
| Accumulated Deficit | $(661,814) | $(644,181) |
Note: Q3 2025 marked the company's first quarterly net income since inception, driven by strong revenue growth and a tax benefit.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 47% year-over-year in Q3 2025 ($133.0M vs. $90.4M). Product sales grew to $133.0M, driven by Livmarli ($92.2M) and Bile Acid Medicines ($40.8M).
- Profitability: The company reported a net income of $2.9M in Q3 2025, a reversal from a net loss of $14.2M in Q3 2024. This was aided by a $0.3M tax benefit resulting from the "One Big Beautiful Bill Act" (OBBBA), which eliminated the requirement to capitalize domestic R&D costs.
- Expense Increases: Operating expenses rose to $130.4M in Q3 2025 from $103.1M in Q3 2024.
- R&D: Increased $11.3M to $43.0M, primarily due to volixibat trials and the new MRM-3379 program.
- SG&A: Increased $11.4M to $61.9M, driven by personnel growth and stock-based compensation.
- Cost of Sales: Increased $4.7M to $25.5M, largely due to higher royalty expenses on increased sales.
- Liquidity: Unrestricted cash, cash equivalents, and investments totaled $378.0M as of September 30, 2025, up from $292.8M at year-end 2024.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue generating net losses for the foreseeable future despite Q3 profitability, due to ongoing clinical trials, commercialization costs, and potential milestone payments. They believe current capital resources are sufficient for at least 12 months.
- Convertible Notes: The company's 4.00% Convertible Senior Notes due 2029 ($316.2M principal) are currently convertible at the option of holders during Q4 2025 because the stock price exceeded 130% of the conversion price for the requisite period. The company may settle conversions in cash, stock, or a combination.
- Key Risks:
- Regulatory & Clinical: Risks associated with the success of the EXPAND study (Livmarli), VISTAS (volixibat in PSC), and VANTAGE (volixibat in PBC) trials.
- Competition: Potential competition from generic entrants for Bile Acid Medicines (Cholbam/Ctexli) and competitors like Ipsen (Bylvay/Kayfanda) and GSK (linerixibat) in the cholestatic liver disease space.
- Supply Chain: Reliance on third-party manufacturers and sole-source suppliers.
- Intellectual Property: Lack of patent protection for certain approved medicines (Chenodal/Ctexli, Cholbam) and reliance on regulatory exclusivity.
Investor Verification Checklist
- Verify the sustainability of the Q3 2025 net income, specifically the impact of the OBBBA tax provision and whether it is a one-time benefit.
- Monitor the conversion activity of the $316.2M convertible notes in Q4 2025 and the potential dilution or cash outflow associated with settlements.
- Review upcoming clinical trial data timelines for volixibat (PSC/PBC) and the Livmarli EXPAND study to assess pipeline value.
- Assess the competitive landscape for Bile Acid Medicines, specifically the threat of generic competition given the lack of patent exclusivity.
- Confirm the company's ability to maintain liquidity given the high burn rate associated with R&D and commercialization, despite the recent cash position of $378M.